Sanofi loses bid to revive Lantus Solostar insulin-pen patents

In a win for Sanofi-competitor Viatris, Sanofi's attempt to keep its patent for the blockbuster insulin injection pen, Lantus SoloStar, has been rejected by the US Court of Appeals.
Photo: CHARLES PLATIAU/Reuters / X00217
Photo: CHARLES PLATIAU/Reuters / X00217
By Susan Decker, bloomberg

Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading